Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update
Arcus reported Q1 revenue of $17 million, down from $28 million in the prior year, with a net loss of $128 million. The company announced the discontinuation of its Phase 3 STAR-121 study evaluating domvanalimab plus zimberelimab in first-line NSCLC due to futility, marking a setback for its TIGIT program. Offsetting the news, Arcus holds $876 million in cash providing a runway into the second half of 2028 and expects full-year 2026 revenue between $50 million and $65 million.
Key figures
- Revenue
- $17 million
- Guidance
- GAAP revenue of between $50 million and $65 million for the full year 2026
- Net loss
- $128 million
- Cash runway
- at least the second half of 2028
- Rd expenses
- $122 million
- Cash position
- $876 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.